

MONOBUTYRIN : A NEW ANTIBACTERIAL MOLECULE FOR ANIMAL HEALTH, WITH GROWTH PROMOTING EFFECTS

M. Parini ^(a), P. Massi ^(b), G. Tosi ^(b), E. Marco, M. Porowski

^(a) SILO SpA; ^(b) Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna – Forlì

Corresponding Author: Manuela Parini: manuela.parini@silospa.com

The EU Antibiotic Growth Promoters ban has led to an increased usage of antibiotics as therapeutics, including those that are of direct importance in human medicine. Antibiotic-resistance, increased diarrhoea, weight loss, mortality, human health hazards and other consequences of antibiotics prescriptions, urge feed producers and scientific communities to search for alternatives at a reasonable cost.

Many studies have shed a light on the positive properties and role of fatty acids (such as butyric acid) in managing animal gut health. Butyric acid has been proven to be particularly beneficial in the formation of intestinal micro-flora, the stimulation of villi growth and the integrity of the digestive track, thus increasing the resistance against pathogens (1).

It was also demonstrated that butyric acid acts directly on the genetic structure of *salmonella enteritidis* and *typhimurium* and inhibits its proliferation(2).

Furthermore, butyric acid, in its undissociated form, can have direct bacteriostatic effects on microorganisms like *E.coli* (3). As a matter of fact, in an acid environment (pH between 4 and 5.5), the butyric acid is found prevalently in its undissociated form, and therefore, it acts as an antibacterial agent(4). The intestinal acidity however varies between pH 6 and 7 in which the butyric acid dissociates resulting in a significant decrease in its antibacterial efficacy. In addition to that, the calcium bicarbonate present in the digestive track reacts with the acids creating a buffering effect. In a study of F. Boyen et al. (Ghent University) the efficacy of butyric acid against 54 porcine *Salmonella Typhimurium* strains was measured in vitro at different pH values. It was found that the MIC (minimum inhibitory concentration) of butyric acid at pH 4 is 5 mM, while at pH 6 the quantity of butyric acid required is 160 mM to inhibit *Salmonella* growth. The efficacy of butyric acid decreases by 32 times against *Salmonella* when pH increases from 4 to pH 6 (5).

The question is: how to combine the favorable effects of direct nutrition of the enterocytes, villi growth stimulation, intestinal mucosa integrity improvement, and at the same time, a strong antibacterial effect in the gut environment at a pH between 6 and 7?


Several studies demonstrated both in vitro as in vivo (5,6), that fatty acids monoglycerides have stronger antibacterial action than the fatty acids themselves.

The idea developed by SILO SpA was to produce and to use in the animal diets the Monobutyryn, which is a monoglyceride of the butyric acid, as a pH-independent antibacterial supplement and to carry butyric acid into the enterocytes as a nutrient and growth enhancer.

The Monobutyryn is obtained by combining a molecule of glycerol with a molecule of butyric acid (figure 1.)


The Monobutyryn is marketed by SILO SpA with the name Monobutyryn – Hydro C4.

Figure 1. Monobutyryn



The Hydrogen atom **H** of glycerol is bound with the **OH** of the butyric acid

Figure 2. Monobutyryn structure



The chemical bond but. Acid / glycerol is not an ionic bond (pH dependent), but a covalent bond (pH independent)

The end product is a low molecular weight (162) and water dispersible molecule. It has one lipophilic and one hydrophilic head, which make it compatible with hydrophilic and lipophilic cell walls / membranes of bacteria. The bond between butyric acid and glycerol is a covalent bond (Figure 2), stable from pH 1 to pH 7 and up to 230°C. This means that the molecule is stable in different environments: water, feed, gizzard, stomach, gut. It starts its activity already in the drinking water or in the feed, in the first digestive tract and in the gut, without losing its properties throughout the digestive tract.

Preliminary tests in vitro have been carried out on some gram-positive and gram-negative bacteria, at pH 4,5 (to reproduce the stomach pH) and at pH 7 (to reproduce the gut pH)

Trial 1 in vitro

The Public Animal Health Institute of Brescia, dr. Loris Alborali, carried out a test on *E.coli* O157, *Salmonella typhimurium* and *Salmonella cholerasuis*, in which the MIC of butyric acid or Monobutyryn have been compared. The MIC of the Monobutyryn resulted to be 2-4 times lower than that of the butyric acid at pH 7. (table 1)

Table 1. Trial 1 in vitro. Determination of the MIC of the free butyric acid or Monobutyryn on swine strains of *Salmonella ss.* and *E.coli* O 157 – Public Animal Health Institute of Brescia - 2010

| Substance | pH | <i>S. typhimurium</i> | <i>S. choleraesuis</i> | <i>E. coli</i> O 157 |
|------------------------|----|-----------------------|------------------------|----------------------|
| Butyric acid | 7 | 0,25% | 0,25% | 0,25% |
| Monobutyryn – Hydro C4 | 7 | 0,06% | 0,12% | 0,12% |

Trial 2 in vitro

An in vitro trial carried out by prof. Steven Leeson – Guelph University, demonstrated that Monobutyryn – Hydro C4 is 3 times stronger in inhibiting the growth of *Clostridium perfringens* CP 27 compared with the butyric acid. In the trial 1000 ppm (0,1%) of Monobutyryn - Hydro C4 was enough to inhibit the growth of *Clostridium perfringens*, while 3000 ppm (0,3%) of butyric acid was necessary to achieve the same effect (Table 2).

Table 2. Trial 2 in vitro. Inoculation with 10⁵ of *Clostridium perfringens* CP 27. Medium: Brain Heart Infusion. Incubation time and growth that had been appeared : + for 24hr, ++ for 37hr and +++ for 96hr; 3 replication for each concentration – From a report by Steve Leeson – Guelph University - 2009

| ppm | pure butyric acid | Monobutyryn - Hydro C4 |
|------|-------------------|------------------------|
| 500 | + | + |
| | + | + |
| | + | + |
| 1000 | + | no growth |
| | + | no growth |
| | + | no growth |
| 1500 | + | no growth |
| | + | no growth |
| | + | no growth |
| 2000 | ++ | no growth |
| | ++ | no growth |
| | ++ | no growth |
| 2500 | ++ | no growth |
| | ++ | no growth |
| | ++ | no growth |
| 3000 | no growth | no growth |
| | no growth | no growth |
| | no growth | no growth |
| 4000 | no growth | no growth |
| | no growth | no growth |
| | no growth | no growth |

Trial 3 in vitro

The Public Animal Health Institute of Forlì (dr. Paola Massi and dr. Giovanni Tosi), carried out a test in vitro in which the efficacy of butyric acid or Monobutyryn - Hydro C4 in reducing the cfu of *Salmonella typhimurium* at pH 4,5 and pH 7 were compared. The data reported in the Table 3 show that at both pH values the efficacy of Monobutyryn – Hydro C4 was 2 times stronger than that of the butyric acid.

Table 3. Trial 3. Anti-salmonella activity of butyric acid or Monobutyryn – Hydro C4 at pH 4,5 or 7

| Substance | mM/liter | pH | Salmonella Typhimurium (cfu/ml) |
|------------------------|----------|-----|---------------------------------|
| Positive Control | | 7 | 120x10 ⁵ |
| Positive Control | | 4,5 | 96x10 ⁵ |
| Butyric acid | 12,4 | 7 | 65x10 ⁴ |
| Butyric acid | 12,4 | 4,5 | 25x10 ³ |
| Monobutyryn - Hydro C4 | 12,4 | 7 | 74x10 ³ |
| Monobutyryn - Hydro C4 | 12,4 | 4,5 | 32x10 ² |

The positive results of the in vitro trials have been also confirmed in the field.

Trial 1 in vivo (Poultry) – Preliminary data

At the Public Animal Health Institute of Forlì (dr. Paola Massi and dr. Giovanni Tosi) three scientific trials were carried out on broiler chickens, aimed at testing the efficacy of different dosages of Monobutyryn – Hydro C4 in reducing the *Salmonella* infection levels in caeca, faeces and livers of orally infected animals. The three studies were conducted in 2009 and 2010 and will be the subject to a dedicated publication. In one of the trials the chickens were orally infected at day 10 post-hatch with 10³ CFU of *S.typhimurium* and the treatment (5 liters of Monobutyryn – Hydro C4 per ton of drinking water) started 5 days post-infection. It was really surprising that with post-infection treatments in the drinking water it was possible to reduce the numbers of positive caeca after enrichment by 80% with 10 days of treatment, and by 100% with 15 days of treatment. Not only 100% of the caeca resulted to be negative for *Salmonella* after enrichment, but also the 100% of the livers and faeces (shedding) showed the same result after the 15-days-treatment. The control group showed 100% of positive caeca until day 20 post-infection, with an average CFU amount of 2220 CFU (50% of the chickens showed CFU amounts between 1700 and 5500). The control group was then treated with 10 litres of Monobutyryn per ton of drinking water only during the last 5 days before slaughtering, to evaluate the possibility to reduce the infection level by treating the animals just some days before slaughtering. As result of the 5 days treatment the control group showed 80% of negative caeca after enrichment, and the average salmonella CFU amount in

the 20% of positive chickens was 250. Some figures are shown in Tables 4 and 5. The subsequent studies carried out by Public Animal Health Institute in Forlì managed to optimize the dosages for salmonella prevention and treatment. All data will be published.

Table 4. Trial 1 in vivo. Presence/absence of *S.typhimurium* in caeca and cfu count of *S.typhimurium* at day 15 post-infection. The chickens were orally infected with 10^3 cfu at day 10 of life. The trial was carried out by the Public Animal Health Institute of Forlì. 2010

| Group | Caeca positive after enrichment | CFU counts in positive caeca (cfu / g) |
|---|---------------------------------|--|
| Control No treatments | 10/10 | 300, 500, 600, 900, 1400, 1700, 3000, 3500, 4800, 5500 |
| T1 Treated for 10 days with Monobutyryn – Hydro C4. The treatment started 5 days post- infection | 2/10 | 300, 500 |


Table 5. Trial 1 in vivo. Presence/absence of *S.typhimurium* in caeca and cfu count of *S.typhimurium* at day 20 post-infection. The chickens were orally infected with 10^3 cfu at day 10 of life. The trial was carried out by the Public Animal Health Institute of Forlì. 2010

| Group | Caeca positive after enrichment | CFU counts in positive caeca (cfu / g) |
|--|---------------------------------|--|
| Control Treated with Monobutyryn – Hydro C4 only during the last 5 days before slaughtering | 2/10 | 100, 300 |
| T1 Treated for 15 days with Monobutyryn – Hydro C4. The treatment started 5 days post-infection | 0/10 | 0 |

Trial 2 in vivo (Swine) – Preliminary data

Some preliminary results of a trial carried out under the supervision of the Public Animal Health Institute in Brescia, dr. Loris Alborali, show the efficacy of Monobutyryn – Hydro C4 in controlling the enteric pathologies. The trial is still ongoing and will be subject to a dedicated publication. 1332 animals are involved in the trial (678 animals in the control group and 653 animals in treated group). During the observed period from 23rd of June to August 1st 2010 (from day 41 to day 91 of age) the number of injection related to enteric diseases was 53 in the control group, and only 5 in the group treated with 0,2% of Monobutyryn – Hydro C4 in the drinking water. (Figure 3)

Figure 3. Trial 2 in vivo. Number of injections for diarrhea control in 2 groups of pigs from day 41 to day 91 of age. Trial carried out under the supervision of the Public Animal Health Institute of Brescia. 2010




This trend is commonly observed in the field where Monobutyryn – Hydro C4 is used in the drinking water or in the feed. In many cases Monobutyryn – Hydro C4 is used as substitution of zinc oxide and as alternative to antibiotics to control *E.coli*, *clostridium*, and other enteric pathologies like *Brachispira* and *Lawsonia*, specially in case of antibiotic-resistance in the farms. Some practical examples are reported here below.


Trial 3 in vivo – (Swine)

In a consulted by dr. Marian Porowski Polish farm of 1700 sows (positive for PRRS, Mhp, PCV2) with open production cycle, average weaning age at 28 days, 25,5 weaned piglets per sow per year, the main problem was Colibacteriosis in the after post-weaning period, in the feed transition phase and when animals entered into the fattening period. The following program was implemented: 3 liters of Monobutyryn – Hydro C4 per 1000 liters of drinking water were administered during the 4 days before and the 4 after the transition from pre-starter to starter feed, for 7 days before entering the fattening units and 7 day after the placement of the animal in the fattening units. Monobutyryn – Hydro C4 was used as zinc oxide and antibiotics replacement. The mortality was reduced after 6 months of Monobutyryn – Hydro C4 use from 3,5% to 1,9% in the fatteners and from 2,5% to 1,3% in the weaners (Figures 4 and 5).

**Figure 4. Trial 3 in vivo.
Mortality in fattening pigs
6 months before and 6 months after
the use of Monobutyryn – Hydro C4**



**Figure 5. Trial 3 in vivo.
Mortality in weaning piglets 6 month
before and 6 months after the use of
Monobutyryn – Hydro C4**



Trial 4 in vivo (Swine)

In a Spanish farm with 7000 finishing herd the mortality due to Sudden death (Clostridium like process) was a severe problem during the first 6 months of 2009. Up to 38% of total mortality was caused by sudden death syndrome. Monobutyryn – Hydro C4 was administered in the drinking water (2 liters per ton of water) in the second semester of 2009. After this, not only the mortality was reduced by half due to clostridiosis, but also productivity was improved (-15% in FCR) and the costs of medications was reduced by 47% (Tables 6 and 7)

Table 6. Trial 4 in vivo. Performance results, medication costs and costs for kg of produced meat in a farm 6 months before and 6 months after the use of Monobutyryn – Hydro C4

| Measured parameters | 1 st semester 2009 before the use of Monobutyryn | 2nd semester 2009 Use of Monobutyryn | Variation | Variation as % |
|---|---|---|-----------|----------------|
| FCR | 2,77 | 2,35 | -0,420 | -15% |
| ADG | 0,758 | 0,764 | 0,006 | |
| Total costs of medications for each animal in Euros | 3,14 | 1,65 | -1,485 | -47% |
| Cost per kg of produced meat in Euros | 1,03 | 0,97 | -0,060 | -6% |

Table 7. Trial 4 in vivo. Percentage of mortality due to hemorrhagic syndrome and total medications cost in a farm 6 months before and 6 months after the use of Monobutyrim – Hydro C4

| | % Dead hemorrhagic syndroms / total dead | Costs of medications in the feed for each animal | Total costs of medications |
|--|--|--|----------------------------|
| January-09 | 13,7 | 2,50 | 2,94 |
| February-09 | 35,0 | 2,28 | 2,83 |
| March-09 | 42,2 | 3,03 | 3,40 |
| April-09 | 41,7 | 2,60 | 2,94 |
| May-09 | 46,9 | 1,82 | 2,04 |
| June-09 | 45,8 | 2,88 | 4,67 |
| Start of treatment with Monobutyrim – Hydro C4 | | | |
| July-09 | 34,6 | 0,67 | 3,05 |
| August-09 | 24,8 | 0,20 | 0,38 |
| September-09 | 25,5 | 0,15 | 1,94 |
| October-09 | 20,4 | 0,01 | 0,65 |
| November-09 | 22,4 | 0,00 | 1,95 |
| December-09 | 21,4 | 0,00 | 1,94 |
| January-10 | 15,0 | 0,00 | |

Trial 5 in vivo - (Poultry)

It is further interesting to observe that also the butyric acid in the monobutyrim molecular form (Monobutyrim – Hydro C4) is able to enhance villi growth. In a study conducted on broiler chickens by Prof. Roman Halouzka - University of Veterinary and Pharmaceutical Sciences of Brno, Institute of Pathological Morphology (2008) it was observed that the administration of 0,2% of the product Monobutyrim - Hydro C4 in the drinking water increased villi length in Meckels diverticulum area (+13,75%), in the ileum zone (+12,37%) and in the ileocecal valve zone (+1,84%) (Figure 8 and Figure 9). Concerning the effects on villi in the ileocaecal valve zone, Prof. Roman Halouzka wrote the following comment in his scientific report: „*The results show, and you can see it clearly, that the height of villi in some chicken groups increases towards the large intestine, which is a surprising finding.*“

Figure 8. Trial 5 in vivo. Data from the Report made by the University of Veterinary and Pharmaceutical Sciences Brno Institute of Pathological Morphology - Prof. Roman Halouzka. 2008. Villi height in chickens fed unsupplemented diet or the product Monobutyryn - Hydro C4 in the drinking water







Figure 9. trial 5 in vivo. Data from the Report made by the University of Veterinary and Pharmaceutical Sciences Brno Institute of Pathological Morphology - Prof. Roman Halouzka. 2008 Gut morphology of chickens fed unsupplemented diet or Monobutyryn - Hydro C4-30 in the drinking water





Conclusion

In the everyday field practice and the scientific trials Monobutyryn – Hydro C4 proved to have strong pH-independent antibacterial properties, particularly against *E.coli*, *Salmonella spp.*, *Clostridium spp.*, *Brachispira hyodysenteriae*, *Lawsonia intracellularis*. Since it is water dispersible, it can be administered in the drinking water or in the feed. The effects against pathogens are performed in water and throughout the whole digestive tract (stomach, gizzard, gut).

The positive effects of Monobutyryn – Hydro C4 on villi growth and gut integrity, combined with its antibacterial action, allow to improve performance with an economical return both in terms of FCR improvement and lower costs of medications. These characteristics of the Monobutyryn – Hydro C4 will fit very well in antibiotic reduction programs to be applied in animal husbandry.

REFERENCES

1. **R. Claus, D. Günthner, H. Letzguß.** 2007. Effects of feeding fat-coated butyrate on mucosal morphology and function in the small intestine of the pig. *Journal of Animal Physiology and Animal Nutrition.* **91:** 312–318
2. **I. Gantois, R. Ducatelle, F. Pasmans, F. Haesebrouck, I. Hautefort, A. Thompson, J. C. Hinton, and F. Van Immerseel.** 2006. Butyrate Specifically Down-Regulates Salmonella Pathogenicity Island 1 Gene Expression. *Applied and Environmental Microbiology.* **72:** 946-949
3. **P. Galfi,** reported in **G.Piva.** 4th International Feed Production Conference, 1996-February 22-23, Piacenza
4. **Nakaj S., Siebert K.,J.** 2003. Validation of bacterial growth inhibition models based on molecular properties of organic acids *Int. J. of Food Microbiology,* 2003, **86:**249-255
5. **F. Boyen, F. Haesebrouck, A. Vanparys, J. Volf, M. Mahu, F. Van Immerseel, I. Rychlik, J. Dewulf, R. Ducatelle, F. Pasmans.** 2008. Coated fatty acids alter virulence properties of Salmonella Typhimurium and decrease intestinal colonization of pigs. *Veterinary Microbiology.* 132: 319-327
6. **Kabara, J. J., Swieczkowski, A.J. Conley, J.P. Truant.** 1972. Fatty acids and derivatives as antimicrobial agents. *Antimicrob. Agents and Chemioth.* **2-1,** 23-28
7. **Thormar, H., H. Hilmarsson, and G. Bergsson.** 2006. Stable concentrated emulsions of 1-monoglyceride of capric acid (monocaprin) with microbicidal activities against the foodborne bacteria *Campylobacter jejuni*, *Salmonella spp.* and *Escherichia coli*. *Appl. Environ. Microbiol.* **72:**522–526